CytoMed Therapeutics Long Term Debt

CytoMed Therapeutics posts a long-term debt of $420K as of December 2025. That compares with $310K in the prior-year period — up 38.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CytoMed Therapeutics's long-term debt was $310K. The latest reading is $420K — a 38.0% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of CytoMed Therapeutics's financial statement story. At $420K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GDTC's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; CytoMed Therapeutics's other metric pages and overview cover the third.